 |
|
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
Hung-Yao Lin, Tai-Chung Tseng
Clin Mol Hepatol. 2022;28(2):181-182. Published online 2022 Feb 21 DOI: https://doi.org/10.3350/cmh.2022.0028
|
|
Citations to this article as recorded by
 Tenofovir Alafenamide for Multiple Drug-Resistant Chronic Hepatitis B: A 3-Year Clinical Trial
Jonggi Choi, Young-Suk Lim, Ji-Hoon Kim, Kwan Soo Byun, Byung Chul Yoo
Clinical Gastroenterology and Hepatology.2023; 21(12): 3185. CrossRef Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis
Eui Gwon Hwang, Eun-Ae Jung, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
Hepatology International.2023; 17(4): 860. CrossRef Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?
Jonggi Choi, Won-Mook Choi, Young-Suk Lim
Clinics in Liver Disease.2023; 27(4): 809. CrossRef
|